Cardiovascular Drug Markets in US and Europe Projected for Significant Growth

The U.S. cardiovascular drugs market is forecast to grow from $28.42 billion in 2025 to $37.03 billion by 2035, while Europe's anticoagulants market is expected to reach $23.68 billion by 2033. Both markets are being driven by rising cardiovascular disease prevalence and a rapidly aging population across both regions.

The U.S. market is projected to increase from $29.25 billion in 2026 to approximately $37.03 billion by 2035, expanding at a compound annual growth rate (CAGR) of 2.68% from 2026 to 2035. Growth is primarily fueled by the increasing prevalence of hypertension and heart failure, paired with high demand for convenient oral medications and next-generation combination therapies. By drug type, the anticoagulants segment held a major market share in 2025, while the antihypertensive segment is expected to expand at the fastest CAGR through 2035.

In Europe, the anticoagulants market was valued at $11.63 billion in 2024 and is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22% from 2025 to 2033. Anticoagulants—often called blood thinners—are essential medicines used to prevent and treat conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke. Cardiovascular diseases account for nearly 45% of all deaths in Europe, making them the region’s leading cause of mortality.

A key trend in both regions is the shift toward newer, more convenient therapies. In the U.S., there is a high demand for next-generation combination therapies that enhance patient compliance. In Europe, there is a rapid adoption of Novel Oral Anticoagulants (NOACs), which are gradually replacing older therapies like warfarin. NOACs offer several clinical and practical advantages, including no need for frequent blood monitoring, fewer food and drug interactions, more predictable dosing, and improved patient compliance.

Market dynamics highlight both opportunities and restraints. In the U.S., the market faces constraints from patent expirations and competition from generic drugs, which erode profit margins. However, government initiatives are playing a crucial role in reducing financial barriers for patients, particularly through the Inflation Reduction Act, which allows Medicare to negotiate prices directly with manufacturers.

In Europe, the market is expanding against a backdrop of a major public health challenge, with thrombosis particularly common among people aged 60 years and above. Healthcare systems are placing greater emphasis on preventive care, early diagnosis, and long-term risk management, which further boosts the demand for reliable and patient-friendly anticoagulant therapies. Regulatory oversight by bodies such as the European Medicines Agency (EMA) has strengthened confidence in newer therapies.

Both markets are witnessing technological transformation. In the U.S., artificial intelligence is playing a transformative role by accelerating drug discovery, optimizing clinical trial designs, and personalizing patient pharmacotherapy. The rise of RNA therapeutics and precision genomics is also revolutionizing cardiology by addressing previously intractable lipid and metabolic pathways.